We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.20 | 0.49% | 41.11 | 41.3125 | 40.87 | 40.95 | 2,730,464 | 01:00:00 |
From Apr 2019 to Apr 2024
By Adriano Marchese
GlaxoSmithKline PLC (GSK.LN) said Monday that has found positive data over a 96-week period from phase 3 study of investigational Fostemsavir in patients with HIV.
ViiV Healthcare, of which GlaxoSmithKline is a majority shareholder, said rates of virologic suppression and immunologic response increased from week 48 to week 96 in a difficult-to-treat population with multi-drug resistant HIV-1.
The study found that at week 96, 60% of patients receiving Fostemsavir as well as optimized background treatments in the randomized cohort achieved virologic suppression--an increase of 6% from week 48 results.
ViiV plans to begin the submission of regulatory applications for Fostemsavir with the U.S. new-drug application later this year.
Write to Adriano Marchese at adriano.marchese@dowjones.com
(END) Dow Jones Newswires
July 22, 2019 12:37 ET (16:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
